ArticleFrontiers in immunology2025
PILRA serves as a diagnostic and prognostic biomarker and modulates the tumor immune microenvironment and immunotherapy response in breast cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Paired immunoglobulin-like type 2 receptor alpha (PILRA) is a membrane-associated receptor involved in immune regulation and signal transduction. However, its expression and functional role in breast cancer remain largely unknown. This study investigated the expression, mutation, and DNA methylation patterns of PILRA in breast cancer, along with its impact on immune infiltration and associated pathways. We also evaluated its potential as a therapeutic target for predicting prognosis and guiding immunotherapy in breast cancer. Methods: PILRA expression in breast cancer was analyzed using TCGA and GTEx datasets. Protein expression in breast cancer and adjacent normal tissues was evaluated by immunohistochemistry, and expression levels were validated by RT-qPCR in 50 paired tumor and adjacent tissue samples. cBioPortal was used to assess mutation profiles and prognostic relevance. Associations with drug resistance were examined by analyzing relationships to resistance- and sensitivity-related genes. DNA methylation and its prognostic impact were analyzed using MethSurv. The prognostic and diagnostic value of PILRA was evaluated through survival and ROC curve analyses. Single-cell and tissue expression data were obtained from HPA and GTEx, and gene effect score from DepMap. Immune associations were assessed using TISIDB. Gene correlation and protein-protein interaction networks were analyzed via TCGA and STRING, followed by KEGG and GO enrichment. Results: PILRA expression was upregulated in breast cancer tissues and associated with poor survival and drug resistance. We identified R236M as the dominant mutation site and found that its mutation is linked to improved prognosis. PILRA methylation downregulated its expression and correlated with better prognosis. Survival analysis and ROC curves supported the potential of PILRA as a prognostic biomarker. PILRA was involved in immune infiltration and modulated the abundance of various immune cells and the tumor microenvironment, suggesting a role in immune regulation and tissue maintenance. Correlation and enrichment analyses revealed that PILRA-associated genes were mainly involved in cancer-related processes and pathways, with key hub genes in the PPI network. Conclusion: We identified PILRA as a diagnostic and prognostic biomarker in breast cancer and analyzed its association with immunotherapy response. The findings provide new insight and potential strategies for breast cancer diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.